1JBU
| Coagulation Factor VII Zymogen (EGF2/Protease) in Complex with Inhibitory Exosite Peptide A-183 | Descriptor: | BENZAMIDINE, COAGULATION FACTOR VII, Peptide exosite inhibitor A-183, ... | Authors: | Eigenbrot, C, Kirchhofer, D, Dennis, M.S, Santell, L, Lazarus, R.A, Stamos, J, Ultsch, M.H. | Deposit date: | 2001-06-06 | Release date: | 2001-07-11 | Last modified: | 2023-08-16 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | The factor VII zymogen structure reveals reregistration of beta strands during activation. Structure, 9, 2001
|
|
1N4Y
| REFINED STRUCTURE OF KISTRIN | Descriptor: | KISTRIN | Authors: | Krezel, A.M, Krane, J, Dennis, M.S, Lazarus, R.A, Wagner, G. | Deposit date: | 2002-11-02 | Release date: | 2003-01-28 | Last modified: | 2012-09-05 | Method: | SOLUTION NMR | Cite: | Solution structure of kistrin, a potent platelet aggregation inhibitor and GP IIb-IIIa antagonist. Science, 253, 1991
|
|
1DVA
| |
8G0M
| Structure of complex between TV6.6 and CD98hc ECD | Descriptor: | 1,2-ETHANEDIOL, 4F2 cell-surface antigen heavy chain, TETRAETHYLENE GLYCOL, ... | Authors: | Kariolis, M.S, Lexa, K, Liau, N.P.D, Srivastava, D, Tran, H, Wells, R.C. | Deposit date: | 2023-01-31 | Release date: | 2023-10-18 | Method: | X-RAY DIFFRACTION (2.25 Å) | Cite: | CD98hc is a target for brain delivery of biotherapeutics. Nat Commun, 14, 2023
|
|
6VVU
| Anti-Tryptase fab E104.v1 bound to tryptase | Descriptor: | CALCIUM ION, Fab E104.v1 heavy chain, Fab E104.v1 light chain, ... | Authors: | Ultsch, M, Koerber, J.T. | Deposit date: | 2020-02-18 | Release date: | 2020-12-30 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (3 Å) | Cite: | Bivalent antibody pliers inhibit beta-tryptase by an allosteric mechanism dependent on the IgG hinge. Nat Commun, 11, 2020
|
|
6O1F
| |
4K3J
| Crystal structure of Onartuzumab Fab in complex with MET and HGF-beta | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Hepatocyte growth factor, Hepatocyte growth factor beta chain, ... | Authors: | Ma, X, Starovasnik, M.A. | Deposit date: | 2013-04-10 | Release date: | 2013-08-28 | Last modified: | 2023-09-20 | Method: | X-RAY DIFFRACTION (2.8 Å) | Cite: | Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc.Natl.Acad.Sci.USA, 110, 2013
|
|
3HR5
| |
6W3H
| Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ATV Fc, Transferrin receptor protein 1,Transferrin receptor protein 1 | Authors: | Srivastava, A, Kariolis, M, Wells, R. | Deposit date: | 2020-03-09 | Release date: | 2020-06-10 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (3.38 Å) | Cite: | Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. Sci Transl Med, 12, 2020
|
|